Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo Hospital, 113-8655, 7-3-1, Hongo, Bunkyo-Ku, Tokyo 113-8655, Japan.
Department of Orthopaedic Surgery, Musashino Red Cross Hospital, Sakaiminami Cho 1-26-1, Musashino City, Tokyo 180-8610, Japan.
Spine J. 2018 Dec;18(12):2205-2212. doi: 10.1016/j.spinee.2018.04.015. Epub 2018 Apr 26.
Recent reports suggested that placing vancomycin powder into surgical wounds before closure can prevent surgical site infections (SSIs) in spinal surgery.
The present study aimed to evaluate if intrawound vancomycin powder could prevent SSIs after spinal surgery with posterior instrumentation.
This is a multicenter retrospective cohort study using propensity score matching.
We reviewed all spinal surgeries performed with posterior instrumentation from July 2012 to December 2014 at 11 institutions among patients aged ≥15 years.
The incidence of SSIs was compared between patients who received intrawound vancomycin powder (vancomycin group) and those who did not (control group).
Demographic and operative data and microbiological findings of SSI cases were analyzed. After a preliminary whole-cohort analysis, we performed one-to-one propensity score matching to adjust for the differences between the two groups and then compared the incidence of SSIs between the matched groups. No funds were received in support of this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.
A total of 2,859 patients were included in the study. In the vancomycin and control groups (n=694 and n=2165, respectively), 12 (1.73%) and 21 (0.97%) patients developed SSIs, respectively, but the difference was not statistically significant (p=.10, chi-square test). During the propensity score-matched analysis, 507 pairs were analyzed. No significant change in the rate of SSIs was seen between the vancomycin and control groups (8 SSIs [1.58%] vs. 9 SSIs [1.78%], respectively; p=.81, chi-square test). Microbiological analysis revealed that 5 of 12 (42%) and 11 of 21 (52%) SSIs in the vancomycin and control groups, respectively, were caused by Staphylococcus (p=.72, Fisher exact test).
Intrawound application of vancomycin powder was not associated with a significant decrease in the incidence of SSIs after posterior instrumented spinal surgeries in a propensity score-matched analysis. However, the rate of infections caused by Staphylococcus species was lower in the vancomycin group.
最近的报告表明,在关闭切口前将万古霉素粉末置于手术伤口中,可以预防脊柱手术中的手术部位感染(SSI)。
本研究旨在评估后路内固定脊柱手术后,伤口内使用万古霉素粉末是否可以预防 SSI。
这是一项使用倾向评分匹配的多中心回顾性队列研究。
我们回顾了 2012 年 7 月至 2014 年 12 月期间在 11 个机构中,年龄≥15 岁接受后路内固定脊柱手术的所有患者。
比较使用伤口内万古霉素粉末(万古霉素组)和未使用(对照组)的患者的 SSI 发生率。
分析 SSI 病例的人口统计学和手术数据以及微生物学发现。在对全队列进行初步分析后,我们进行了一对一的倾向评分匹配,以调整两组之间的差异,然后比较匹配组之间 SSI 的发生率。本研究未获得任何资金支持。作者与本文主题直接或间接相关的商业方无任何形式的利益。
共纳入 2859 例患者。在万古霉素组(n=694)和对照组(n=2165)中,分别有 12(1.73%)和 21(0.97%)例患者发生 SSI,但差异无统计学意义(p=0.10,卡方检验)。在倾向评分匹配分析中,分析了 507 对。万古霉素组和对照组 SSI 发生率无显著差异(8 例 SSI[1.58%] vs. 9 例 SSI[1.78%],p=0.81,卡方检验)。微生物学分析显示,万古霉素组和对照组的 12 例 SSI 中有 5 例(42%)和 21 例 SSI 中有 11 例(52%)由金黄色葡萄球菌引起(p=0.72,Fisher 确切检验)。
在倾向评分匹配分析中,后路内固定脊柱手术后伤口内应用万古霉素粉末与 SSI 发生率的显著降低无关。然而,万古霉素组由金黄色葡萄球菌引起的感染率较低。